Cancer cells reprogramme one-carbon metabolism (OCM) to sustain growth and proliferation. Depending on cell demands, serine hydroxymethyltransferase (SHMT) dynamically changes the fluxes of OCM by reversibly converting serine and tetrahydrofolate (THF) into 5,10-methylene-THF and glycine. SHMT is a tetrameric enzyme that mainly exists in three isoforms; two localize in the cytosol (SHMT1/SHMT2a) and one (SHMT2) in the mitochondria. Both the cytosolic isoforms can also translocate to the nucleus to sustain de novo thymidylate synthesis and support cell proliferation. Finally, the expression levels of the different isoforms are regulated to a certain extent by a yet unknown crosstalk mechanism. We have designed and fully characterized a set of three SHMT1 mutants, which uncouple the oligomeric state of the enzyme from its catalytic activity. We have then investigated the effects of the mutations on SHMT1 nuclear localization, cell viability and crosstalk in lung cancer cells (A549; H1299). Our data reveal that in these cell lines de novo thymidylate synthesis requires SHMT1 to be active, regardless of its oligomeric state. We have also confirmed that the crosstalk between the cytosolic and mitochondrial SHMT actually takes place and regulates the expression of the two isoforms. Apparently, the crosstalk mechanism is independent from the oligomeric state and the catalytic activity of SHMT1.
Introduction
Alteration of the one-carbon metabolism (OCM) is a recognized hallmark of cancer. Tumour cells recycle one-carbon units from different amino acids within the folate and methionine cycles to produce the building blocks needed to sustain high proliferation rates [1] [2] [3] . The uptake of serine, the major source of one-carbon units, is coupled to a hijacking of glycolysis intermediates towards the serine synthesis pathway (SSP). Serine fuels the folate cycle through the reaction catalysed by serine hydroxymethyltransferase (SHMT) that reversibly interconverts serine and tetrahydrofolate (THF) to glycine and 5,10-methylene-THF (Fig. 1) . Given its pivotal role in OCM, it is not surprising that SHMT is considered a potential drug target for cancer therapy [4] [5] [6] [7] . SHMT is a pyridoxal-5 0 -phosphate (PLP)-dependent enzyme that exists in two main isoforms, which localize in the cytosol (SHMT1) and in the mitochondria (SHMT2). Together with SHMT1 and SHMT2, a third main isoform is expressed, SHMT2a, which has the same sequence of SHMT2 but lacks the N-terminal mitochondrial import signal (Fig. 1) .
It has been shown that serine is mainly catabolized in the mitochondria, where SHMT2 converts it into glycine, directing the folate cycle towards the production of: (a) NADPH used for redox homeostasis, and (b) formate that shuttles one-carbon unit in the cytosol to sustain nucleotide synthesis and DNA methylation [1, 2] . On the other hand, the role of SHMT1 is more likely to regulate the OCM by directing the folate cycle, thus controlling the fate of the one-carbon units, in response to cellular needs [1] . In addition to this enzymatic function, both SHMT1 and SHMT2a are known to undergo small ubiquitin-like modifier (SUMO)-dependent translocation into the nucleus. Here they participate to the assembly of a ternary complex with dihydrofolate reductase (DHFR) and thymidylate synthase (TYMS), which likely binds to the replication fork providing thymidine in situ for
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DNA replication and repair [8, 9] (Fig. 1) . Within this nuclear complex, SHMT1 and SHMT2a were suggested to have a scaffolding role, rather than a catalytic one [10] . In agreement with its nuclear function, we demonstrated that SHMT1 knockdown induces apoptosis in lung cancer cells by causing uracil misincorporation [11] . Finally, in lung cancer cell lines (A549 and H1299), knockdown of SHMT1 expression by RNA interference (iRNA) results in the upregulation of SHMT2, indicating that the cytosolic enzyme can cross-regulate the other two isoforms [11] .
From a structural point of view, SHMT is a tetrameric protein whose quaternary structure is better described as a dimer of obligate dimers ( Fig. 2A) . The active site is located at the interface of the obligate dimer, where PLP is bound to a lysine residue forming the internal aldimine and interacting with residues belonging to both subunits of the obligate dimer. Interestingly, only higher organisms display tetrameric SHMTs, whereas the bacterial homologues are dimeric. This suggests that the tetrameric state may be linked to a more sophisticated allosteric regulation of the enzymatic activity and/or to a nonenzymatic function. Indeed, with respect to the dimeric SHMTs, tetrameric enzymes are able to bind polyglutamylated-THF with an affinity that increases with the number of glutamate units [12, 13] , allowing for a fine tuning of the folate cycle, and therefore adding another regulatory level to the enzymatic activity of SHMT. It is not clear, however, if the tetrameric state of SHMT is also crucial in the assembly of the nuclear complex with DHFR and TYMS or plays a role in the regulation of the expression levels of the different SHMT isoforms.
We have also previously shown that a complex conformational equilibrium exists for human SHMTs in response to PLP availability, with apo-SHMT1 retaining the tetrameric assembly while apo-SHMT2 undergoes a dimer/tetramer equilibrium that is summarized in Fig. 2B [14] . A PLP-dependent change in the oligomeric state of SHMT, also observed for SHMT2 from Pichia pastoris [15] , could in turn be related to different post-transcriptional modification (PTM) of the enzyme. A recent study shows that SHMT2 can be inactivated by succinylation of the catalytic lysine and that the modified enzyme is dimeric [16] . It is unclear whether the different conformational equilibria experienced by SHMT isoforms are in any way related to the protein ability to assemble the nuclear tertiary complex or may be involved in the cross-regulating mechanism between the two isoforms.
In order to investigate what is the role that the oligomeric state of SHMT1 and its catalytic activity play in the nuclear function and/or in the crosstalk between different isoforms, we designed and structurally characterized a set of SHMT1 mutants to purposely uncouple the tetrameric state of the enzyme (scaffolding function) from its catalytic properties (enzymatic function).
Results
Design of the SHMT1 toolset of mutants Figure 2C schematically illustrates the required characteristics of the three mutants that were designed in order to uncouple the oligomeric state from the catalytic properties of SHMT1: (a) a dimeric catalytically active mutant (active dimer: SHMT1-AD, H135N-R137A); (b) a tetrameric inactive mutant, which is unable to form the internal aldimine with PLP and to bind THF (inactive tetramer: SHMT1-IT, K257Q-Y82A-Y83F) [17] ; (c) a tetrameric active mutant with a modified, less stable, tetrameric interface (active unstable tetramer: SHMT1-AUT, H135N-R137A-E168N). The latter, designed to alter the allosteric regulation (if any) between the two obligate dimers, was obtained by adding a further mutation to SHMT1-AD. Interestingly, we were able to restore the tetrameric assembly by generating new H-bonds between the mutated asparagine side chains at position 168 ( Figs 2C and 3) .
The modified interface interactions of SHMT1-AUT were confirmed by X-ray crystallography; we solved the crystal structure of this mutant at 3. 6 A resolution. The mutant crystallized as a tetramer in the P4 3 2 1 2 tetragonal space group. Despite the low resolution of the data, a strong positive electron density peak is clearly observed in the tetrameric interface region corresponding to the mutated residues Asn-168, indicating that an H-bond interaction between the two pairs of homologous side chains is indeed present in SHMT1-AUT (Fig. 3) . These new H-bonds are less stable than the native interactions between the four His-135 (pairwise parallel p-p-staking) and the two salt bridges formed by Arg-137 and Glu-168 ( Fig. 2A ), yet they are still able to keep SHMT1-AUT mainly in a tetrameric state.
Biophysical characterization of the mutants
We determined the oligomeric state of the three mutants by a combination of size exclusion chromatography (SEC) and analytical ultracentrifugation (AUC). SHMT1-AD and SHMT1-IT displayed their expected oligomeric state (dimeric and tetrameric respectively), whereas the SEC profile of SHMT1-AUT was a mixture of both tetrameric and dimeric forms (Fig. 4A) . The tetramer/dimer equilibrium of SHMT1-AUT was PLPdependent, with PLP shifting the oligomeric state towards the tetrameric form, since the fraction of dimeric protein was significantly reduced when PLP was [26] ). The two obligate dimers are coloured in light/dark green and orange/red, respectively. One of the four active sites is highlighted together with the interactions of the key residues at the tetrameric interface (highlighted in green); His-135 making a pp-stacking interaction and Arg-137 forming a salt bridge with Glu-168. Each monomer provides one H-R-E triad; therefore, the tetrameric interface is build upon the interaction of twelve symmetric residues (four triads). (B) Simplified scheme of the conformational equilibrium of SHMT isoforms in response to PLP availability (for more details see [14] ). The two subunits of each obligate dimer are shown in dark and light grey, the tetrameric interface is indicated by a green line. Both holo and apo SHMT1 are tetrameric, while apo-SHMT2 undergoes a tetramer/dimer equilibrium. The dimeric form of the enzyme undergoes a further conformational equilibrium, since the dimer may exist in a closed or in an open conformation, as observed in the apo-SHMT2 crystal structure (pdb ID: 3OU5 unpublished). In the latter, the two monomers are shifted apart to a maximum distance of 10 A and several loops surrounding the active site are unfolded. PLP binding at the active site drives the folding of the disordered loops, stabilizing the interface of the obligate dimer in the canonical closed conformation, thus shifting the dimer/tetramer equilibrium towards the tetrameric form. It must be noticed that the tetrameric assembly can only derive from the assembly of two obligate dimers in the closed conformation, since in the open conformation the key residues located at the tetrameric interface (see panel A) are moved apart and cannot interact. The whole scheme is simplified since PLP may of course bind to all the apo forms. (C) A schematic representation of the desired features of the mutants set. The introduced mutations and the corresponding effects on the oligomeric state or catalysis are indicated below each mutant. The four active sites are indicated with the circles, and the native tetrameric interface with a green line. present in the running buffer (Fig. 4B) . However, for the SHMT1-AUT mutant, the oligomerization equilibrium was revealed only during the SEC run (due to the continuous separation of the species), while the AUC profile showed one single peak indicating that the mutant is mainly tetrameric in solution (Fig. 4C ). This behaviour of the SHMT1-AUT closely recalls the conformational heterogeneity that we have previously described for the mitochondrial isoform SHMT2 [14] .
It must be noticed that the mutation introduced in both SHMT1-AD and SHMT1-AUT, located at the tetrameric interface, are almost 20
A away from the PLP binding site, yet the cofactor binding mode appears to be significantly affected by these mutations as evident from the absorption and CD spectra in the visible region (Fig. 4D,E) . These effects are difficult to assign precisely but are likely correlated to a change in the orientation of the cofactor, which in transferases enzymes is geometrically distorted [18] , and/or an increased disorder (mobility) of the residues of the PLP binding pocket. In particular, with respect to the other samples, the dimeric mutant SHMT1-AD, not only shows a different spectrum but also a relatively low PLP content. Thermal denaturation profiles of the three mutants indicate that, with respect to the wild type, all the mutations also decrease protein stability. Given the order of the apparent T m (SHMT1-AD < SHMT1-AUT = SHMT1-IT < SHMT1-wt), it is interesting to notice that the modification of the tetrameric interface (SHMT1-AUT) or the noncovalent bonding of PLP (SHMT1-IT) destabilize the enzyme to the same extent (Fig. 4F ).
It appears, therefore, that an alteration of the native conformational and oligomerization equilibrium of the enzyme also affects the overall stability, the cofactor binding geometry and, as expected, its affinity.
PLP affinity and catalytic parameters of the mutants
The affinity of SHMT1 mutant forms for PLP was determined by measuring the protein intrinsic fluorescence quenching observed when the cofactor binds to the enzyme (Fig. 5A) [14] . Comparison of the calculated dissociation constants (Table 1) shows that SHMT1-AUT binds PLP with the same affinity with respect to wild-type SHMT2 (e.g. half of wt SHMT1), whereas SHMT1-AD and SHMT1-IT have much lower affinity.
Interestingly, both SHMT1-AUT mutant and wt SHMT2, which share the same PLP-dependent oligomerization equilibrium, have very similar affinity for PLP. Since the active site of the mutant is unaltered this result indicates that by lowering the stability of the tetrameric interface, we also modulated the conformational equilibrium and obtained a very interesting ). A continuous positive electron density peak is observed in the region corresponding to each E168N couple, indicating a pairwise interaction between the same mutated residues of different chains, whereas the same interaction does not take place between the N135 side chain pairs. Two out of four N135 side chain appear to have lower occupancies and do not contribute to the difference map.
SHMT1 mutant, which mimics the SHMT2 behaviour (see Fig. 2B ).
All mutants were also compared with respect to their ability to catalyse the SHMT reaction. SHMT1-AD was inactive, unless a large molar excess of PLP over enzyme was added to the reaction mixture. This was not surprising given its low PLP content. Addition of PLP to the mutant enzyme determined a quite marked instability, as evident from the loss of activity over time, which was 50% after 4 h of incubation at room temperature (Fig 5B-D) . However, such instability did not prevent measurement of the kinetic parameters, which turned out to be similar to those of wild-type SHMT1 (Table 1 and Fig. 5E ). The catalytic properties of SHMT1-AUT were very similar with respect to wt SHMT1 and almost superposable to those of wt SHMT2. As expected, SHMT1-IT was completely inactive, even when assayed in the presence of large PLP molar excess (data not shown).
Nuclear localization of the SHMT1 mutants
The ability of SHMT1 to migrate in the nucleus, in S or G2/M phases, has been previously reported [8, 10] . To study the effect of the mutations on the ability of the proteins to migrate into the nucleus, we produced plasmids to express the SHMT1 mutants as GFP fusion proteins and followed the fluorescence signal in the transfected cells.
We transfected A549 cells with the construct containing SHMT1-wt fused with GFP and, after 24 h, we analysed the cells using a fluorescence microscope. About 50% of the transfected cells showed a GFP-positive fluorescent signal colocalized with the Table 1 .
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The FEBS Journal 285 (2018) 3238-3253 ª 2018 Federation of European Biochemical Societies nuclear marker 4 0 ,6-diamidino-2-phenylindole (DAPI; Fig. 6 ), in agreement with previous reports indicating that the accumulation is related to a specific moment of the cell cycle [10] . We then analysed the cells transfected with the constructs containing the mutants, SHMT1-AD, SHMT1-AUT, or SHMT1-IT, and we observed nuclear accumulation of the fusion protein in all of the mutants in a number of cells comparable to the wt (Fig. 6 ). This indicates that nuclear translocation is independent from both the oligomerization state and the catalytic activity of SHMT1.
Influence of SHMT1 mutants on cell viability
We used Trypan blue exclusion assay and propidium iodide (PI) staining to clarify the effect of SHMT1 mutants expression on A549 and H1299 proliferation and cell survival. In both cell lines, the expression of SHMT1-wt, SHMT1-AD, and SHMT1-AUT did not induce any statistically significant modification in the number of live and dead cells with respect to the cells transfected with the control plasmid (pcDNA). On the other hand, the transfection with the SHMT1-IT induced on both cell lines a slight decrease in cell number after 24 h, which became dramatic after 48 h (Fig. 7) . The cell cycle analysis showed a strong increase of the sub-G1 population in the cells transfected with SHMT1-IT, suggesting an apoptotic induction (Fig. 8) . The observed effects were completely rescued by supplementation of dTMP in the culture medium (Figs 7 and 8) . On the contrary, supplementation with serine glycine and formate had no effect. Overall these data strongly suggest that, at least in our model, the catalytic activity of SHMT1 is necessary for cell survival and proliferation and in particular to absolve its nuclear functions whereas, since SHMT1-AD showed no effect, the oligomeric state appears to have a nonrelevant role on cell survival and proliferation.
Influence of SHMT1 mutants on SHMT2 expression
We previously reported that the iRNA against SHMT1 induces the upregulation of SHMT2 and SHMT2a in lung cancer cells indicating that a certain level of cross-regulation between the isoforms is operative through a yet unknown mechanism [11] .
To study the effect of our toolset of SHMT1 mutants on SHMT2 expression, we transfected A549 and H1299 cells with each of the previously described plasmids and evaluated SHMT2 mRNA and protein expression by quantitative real-time PCR (qRT-PCR) and western blot respectively. Figure 9 shows that the transfection with the wt induces around 20% downregulation of SHMT2 mRNA expression and 10% downregulation of SHMT2 protein levels. This effect is retained only by the SHMT-AD mutant, while the transfection with the SHMT1-AUT and SHMT1-IT does not induce any significant SHMT2 downregulation.
Discussion
The aim of this study was to verify if, and to which extent, the catalytic activity and the oligomeric state of SHMT1 are crucial for its nuclear translocations, for the formation of the tertiary complex with DHFR and TYMS, or for the cross-regulation of the SHMT isoforms expression levels.
All the GFP fused mutants were able to translocate into the nucleus of A549 cells (Fig. 6A) , indicating that neither the catalytic activity nor the oligomeric state are affecting the sumoylation process, which is known to control nuclear translocation during the S and the G2/M phase [10] .
On the contrary, overexpression of the SHMT1-IT mutant in both A549 and H1299 cells showed a strong effect on cell viability, reducing the proliferation rate of almost 60% after 48 h and inducing the accumulation of a sub-G1 population, suggesting an apoptotic phenomenon. Notably, this effect could only be rescued by supplementation of thymidylate, while no rescue was observed when supplementing the medium with glycine, serine and formate. These data suggest that, in lung cancer cells, SHMT1 catalytic activity plays a major role in the nuclear function. Clearly these cells are able to bypass the lack of SHMT1 activity in the cytoplasm but not in the nucleus, where it is essential for dTMP synthesis. This is a strong indication that SHMT1 not only serves in the nucleus as a From [14] .
scaffold to assemble the tertiary complex with DHFR and TYMS and anchor it to the DNA as previously demonstrated [10] but it is also required to provide the substrates needed for de novo dTMP synthesis in situ in order to sustain cell proliferation. On the other hand, no effect on cell proliferation and survival was observed when overexpressing the SHMT1-AD or the SHMT1-AUT, suggesting that the obligate dimer may be the minimal structural unit needed to fulfil the nuclear function. It is important to notice that all the overexpressed mutants are expected to behave as dominant negative with respect to the endogenous wt enzyme, as previously shown for SHMT1-IT [17] . This is because they can form mixed obligate dimers in which one subunit belongs to the mutant and the other to wt SHMT1. Based on these data, our current hypothesis on the nuclear function of SHMT1 is that in situ dTMP synthesis may proceeds through a substrate tunnelling mechanism. If this is the case, all the three enzymes within the nuclear complex are required to be active. We previously demonstrated that downregulation of SHMT1 increases SHMT2 expression in A549 and H1299 cells [11] . In agreement with these observations, here we report that an overexpression of SHMT1 in the same cell lines induces a moderate but significant decrease of SHMT2 expression, confirming that a cross-regulation between the two isoforms indeed exists and SHMT1 appears to repress SHMT2 expression. Surprisingly, only the active dimer displayed an effect similar to the wt, while both SHMT1-AUT and SHMT-IT did not significantly affect SHMT2 levels. Although these results do not allow a clear-cut interpretation, we can state that neither the catalytic activity nor the oligomeric state of SHMT alone play a significant role in the cross-regulation mechanism. Therefore, the repression that SHMT1 exerts on the expression levels of 
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The FEBS Journal 285 (2018) 3238-3253 ª 2018 Federation of European Biochemical Societies SHMT2 must be determined by other factors, yet to be unveiled. At this stage, we cannot exclude that a complex interplay between metabolic fluxes, active site conformational changes, nucleic acid binding or PTM (recently shown to regulate SHMT2 activity [16] ) is actually operative and responsible for the fine tuning of SHMT isoforms levels.
Materials and methods
Mutagenesis
The human shmt1 gene was amplified from a pET28b-shmt1 plasmid (already available) and inserted into the pcDNA3.1(+) (HindIII -XhoI) and pCMV6-AC-GFP (HindIII -XhoI; GFP fused at the C-terminal end of SHMT1) plasmids by standard procedures. The QuickChange lightning mutagenesis kit (Agilent Technologies, Santa Clara, CA, USA) was used to introduce stepwise the following mutations in the three vectors: the double mutant H135N-R137A (SHMT1-AD); H135N-R137A-E168N (SHMT1-AUT); Y82A-Y83F-K257Q (SHMT1-IT). The following (fw) primers were used in stepwise mutagenesis (mutated codons are indicated in bold): H135N-R137A fw-cctggtggaacccaatggggccatcatgggcctg; E168N fw-agaaaa tctctgccacgtccatcttctttaactctatgccctacaag; K257Q fw-caccact caccaccagaccctgcgagg; Y82A-Y83F fw-ggtacccgggccagagat gcctttggcgggact. 
Protein expression and purification
All proteins were expressed as a N-terminal His-tagged fused protein in Escherichiea coli (BL21-DE3) and purified as described for human SHMT2 in Giardina et al. [14] .
Analytical ultracentrifugation
Size distribution of SHMT1 mutants in solution was assessed in sedimentation velocity experiments carried out on a Beckman XLI analytical ultracentrifuge using absorbance optics. The experiments were conducted at 50 350 g and 20°C at a 40 lM protein concentration in 250 mM NaCl, 20 mM Hepes pH 7.2, 5% glycerol and 200 lM PLP. Radial absorbance scans were obtained at 280 nm at a spacing of 0.003 cm with three averages in a continuous scan mode. Sedimentation coefficients were calculated using the software Sedfit [19] and were reduced to water and 20°C (s 20,w ) using standard procedures. Sednterp software (http://rasmb.org/sednterp/) was used to calculate the buffer density and viscosity. The sedimentation coefficient (S) of the mutants was 5.8 for the SHMT1-AD mutant and 7.4 for SHMT1-AUT, consistent with a molecular mass of 100 KDa and 190 KDa respectively, pointing to a dimeric or tetrameric state of the two mutated proteins in solution.
Size exclusion chromatography (SEC)
The analysis was performed by loading 200 lL of protein sample (100-200 lM, subunit concentration) on a FPLC superdex-s200 10/300 column (GE Healthcare) and eluting with 20 mM di Hepes pH = 7.2, 250 mM NaCl, 5% glycerol, AE 200 lM PLP. Apparent molecular weights were estimated after calibration with the following protein standards (Sigma-Aldrich, St Louis, MO, USA): Ferritin (440 KDa); Aldolase (158 KDa); Conalbumin (75 KDa); Ovalbumin (44 KDa); Carbonic anhydrase (29 KDa) and Aprotin (6.7 KDa).
Thermal melting (TM) analysis
Thermal melting (TM) experiments were performed on a JASCO J-710 spectropolarimeter, equipped with a Peltier temperature controller. 400 lL of 7-10 lM protein solution in 20 mM di HEPES pH = 7.2; 250 mM NaCl; 5% glycerol were loaded into a 0.2 cm pathlength quartz cuvette (Hellma, M€ ullheim, Germany). Measurements were performed by increasing the T from 30 to 90°C with a 1°CÁmin À1 ramp. The dichroic signal at 222 nm was acquired with a 0.5°C data pitch.
Measurement of the K d of the PLP binding equilibrium
Equilibria of PLP binding to SHMT1 mutants were analysed taking advantage of the protein intrinsic fluorescence quenching observed upon binding, as previously described [20] . Apo-SHMT samples were prepared by incubation with hydroxylamine 50 mM for 10 min followed by elution on a PD-10 desalting colunm (GE-Healthcare) with 50 mM NaHEPES pH 7.5 containing 100 mM NaCl, 200 lM dithiothreitol and 100 lM EDTA. Subunit concentration was calculated according to a molar absorptivity value at 280 nm of 39 310 cm À1 ÁM À1 [14] . When in the apo-form, all mutants were stable for days if kept on ice. In the fluorometric measurements, the cofactor (from 0.09 to 20 lM) was added to apo-SHMT1 samples (200 nM) at 20°C in 50 mM sodium HEPES, pH 7.2, containing 0.2 mM dithiothreitol and 0.1 mM EDTA. Fluorescence emission spectra (300-450 nm) were recorded in a 1 cm path length quartz cell 15 min after mixing PLP and apo-enzyme, using a FluoroMax-3 Jobin Yvon Horiba (Kyoto, Japan) spectrofluorometer, with the excitation wavelength set at 290 nm. Preliminary experiments demonstrated that the binding equilibrium was established within 10 min. Fluorescence change at 336 nm as a function of PLP concentration was analysed according to a quadratic equation [20] .
Enzymatic assays
The enzymatic activity was measured in a coupled assay that makes use of E. coli methylenetetrahydrofolate dehydrogenase [21] . Kinetic measurements were carried out at 20°C in 20 mM potassium phosphate pH 7.2, containing 200 lM dithiothreitol, 100 lM EDTA and 0.1 lM enzyme. The subunit concentration of holoenzyme forms was calculated according to a molar absorptivity value of e 280 = 47 565 cm À1 ÁM À1 [14] . To determine the K m for L-serine, H 4 PteGlu was maintained at 52 lM while L-serine concentration was varied between 0.15 and 20 mM. L-serine concentration was held at 10 mM and H 4 PteGlu varied in the 3-200 mM range to determine the K m for H 4 PteGlu. In the case of SHMT1-AD and SHMT1-IT, 100 lM PLP was added to the reaction mixture to keep the enzymes in their holo-form.
X-ray crystallography
Both hexagonal and tetragonal crystals of SHMT1-AUT (SHMT1-H135N-R137A-E168N) were obtained at 21°C by hanging drop vapour diffusion methods by equilibrating 2-3 lL of a 80 lM protein solution (in: 250 mM NaCl, 20 mM Hepes pH = 7.2, 5% v/v glycerol, 0.2 mM PLP) with 1-2 lL of reservoir solution containing: 0.1 M sodium cacodylate pH = 6.5, 1.0 M sodium citrate (tetragonal crystals). Crystals were cryo-protected by soaking in a mother liquor solution containing 25% glycerol before flash freezing in liquid nitrogen. A complete data set for each crystal form was collected at a wavelength of 0.96 A on ID30A-3 ESRF beamline, the best crystals diffracted to a maximum resolution of 3.2 and 3. 6 A, hexagonal and tetragonal, respectively. Data were processed with XDS [22] and scaled with Aimless [23] within the CCP4 software suite [24, 25] . The hexagonal crystal belonged to the P6 2 22 space group with the following cell dimensions: a = b = 154.2, c = 236.6 and one molecule in the asymmetric unit. The tetragonal crystal belonged to the P4 3 2 1 2 space group with the following cell dimensions: a = b = 139.7, c = 267.4 and four molecules (one tetramer) in the asymmetric unit. Initial phases were obtained by molecular replacement using SHMT1 wild-type structure as search model (PDB id 1Bj4 [26] ). Since the higher resolution hexagonal crystal contained only one molecule in the asymmetric unit (the obligate dimer and the tetramer are obtained through the crystallographic twofold axes), the side chains at the interface could not be modelled independently. Therefore, cycles of model building and refinement were performed with Coot [27] and Refmac5 [28, 29] only on the tetragonal data set, which contained one tetramer (four molecules) in the asymmetric unit. The geometry of the final tetragonal model was validated with MolProbity [30] . Statistics for data collection and refinement are reported in Table 2 . Coordinates and structure factors have been deposited in the Protein Data Bank with accession code: 6FL5.
Cell lines
A549 and H1299 cancer cells were grown in RPMI-1640 medium supplemented with 2 mM L-glutamine, 100 IUÁmL À1 penicillin/streptomycin and 10% fetal calf serum (SigmaAldrich). For the supplementation experiment, serine 0.4 mM, glycine 0.4 mM, formate 0.5 mM, and dTMP 30 lM have been used (all these reagents are from Sigma-Aldrich).
Trypan blue exclusion assay
The cells have been harvested and after two washes with cold PBS, following the addition of a 0.4% (w/v) trypan blue solution (Sigma-Aldrich), were counted using a Burker chamber (Hirschmann, Germany) using an Axioskop 2 plus microscope (Carl Zeiss Microscopy, Feldbach, Switzerland). Cells staining with trypan blue dye have been considered nonviable.
Propidium iodide (PI) staining
Detached cells were washed with cold PBS, and fixed in 70% ethanol for 3 h. After another wash with PBS, cells were incubated with 1 lgÁmL À1 PI for 3 h at 25°C before cytometric analysis by BD Accuri C6 Flow Cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). Cells were considered apoptotic when their DNA content was < 2n (sub-G1 cell population).
RNA extraction and real-time qRT-PCR analyses
Total RNA was extracted using TRIzol reagent (Invitrogen) following the manufacturer's instructions. About 1 lg of RNA was used for the reverse transcription reaction by using a SuperScript First-Strand Synthesis System Kit (Invitrogen). One microlitre of the 1 : 20 dilution of the cDNA was used for qRT-PCR analysis (in triplicate for each sample) using KAPA Sybr Fast universal qPCR Kit following the manufacturer's instructions. Reactions were performed by Stratagene MX3000P (Stratagene, La Jolla, CA, USA). The primers have been previously reported [4] .
Western Blot
After cells lysis in 8 M urea (Sigma-Aldrich), 40 lg of proteins (protein concentration determined by Biorad Protein Assay; Bio-Rad) were separated by SDS/PAGE and transferred to a nitrocellulose membrane, which was then saturated with 5% BSA in Tris-buffered saline with 0.1% Tween 20. Membranes were incubated with (a) primary antibody for 18 h at 4°C; (b) horseradish peroxidase-conjugated secondary antibody for 1 h at RT; (c) washed with Tris-buffered saline in 0.1% Tween 20 and (d) developed using the chemiluminescence system Chemidoc MP Imaging System (Bio-Rad). Antibody anti-SHMT2, -b-actin and the secondary antibodies anti-goat were from Santa Cruz Biotechnology (Dallas, TX, USA). Densitometry has been performed with NIH-IMAGEJ software (https://imagej.nih. gov/ij/index.html).
Cell transfection
Transient transfection experiments were carried out by seeding cells (1 9 10 5 cells per plate) in six-well dishes in complete medium RPMI-1640. Transfection was performed adding 1 lg per well of pcDNA, pcDNA_SHMT1 or pcDNA_SHMT1 mutant, GFP_SHMT1 or GFP_SHMT1 mutant plasmids 24 h after plating using JetPrime TM (Polyplus transfection, Illkirch, France) reagent following the manufacturer's instructions. Transfection medium was replaced with complete medium RPMI-1640 after 12 h.
Fluorescence microscopy
GFP_SHMT1 variants localization has been performed 24 h after the transfection. Cells were washed with cold PBS and fixed with paraformaldehyde 4% for 20 min at RT. Then washed and permeabilized with PBS 0.2% Triton X-100 for 30 min at RT. After three new washes with PBS, the cells were incubated with DAPI for 60 s, then rinsed for three times and analysed using an AXIO vert.A1 fluorescence Zeiss microscope (Carl Zeiss Microscopy).
Statistical analysis
All data are the mean AE standard deviation of at least three independent experiments. Statistical analysis has been performed using one-way ANOVA followed by Bonferroni comparison. P ≤ 0.05 was considered significant. Percentage of correlation between intensities from random half-data sets.
